[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582872":3},{"organization":4,"outcomesModule":7,"designInfo":65,"detailedDescription":68,"studyPopulation":69,"armGroups":70,"interventions":75,"overallOfficials":64,"centralContacts":80,"locations":64,"responsibleParty":90,"collaborators":64,"id":92,"slug":64,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":105,"studyType":106,"phases":64,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":112,"whyStopped":64,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":64},{"fullName":5,"class":6},"IRCCS San Raffaele Roma","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":64},[9],{"measure":10,"description":11,"timeFrame":12},"2 hour-pain freedom","Percentage of patients reporting complete pain relief within 2 hours after taking the combination of sumatriptan 85 mg and naproxen 500 mg (2h-pain freedom).","2 hours after taking combination of sumatriptan 85 mg and naproxen 500 mg",[14,18,21,24,28,32,35,38,41,45,47,49,51,54,57,60],{"measure":15,"description":16,"timeFrame":17},"1 hour-pain freedom","Percentage of patients reporting complete pain relief within 1 hour after taking the combination of sumatriptan 85 mg and naproxen 500 mg (1h-pain freedom).","1 hour after taking combination of sumatriptan 85 mg and naproxen 500 mg",{"measure":19,"description":20,"timeFrame":12},"2 hour-pain relief","Percentage of patients reporting a 50% reduction in pain intensity within 2 hours after taking the combination of sumatriptan 85 mg and naproxen 500 mg (2h-pain relief)",{"measure":22,"description":23,"timeFrame":12},"Disappearence of Most Bothersome Symptom","Percentage of patients experiencing the disappearance of the Most Bothersome Symptom (MBS: the accompanying symptom of the attack considered most disabling by the patient) within 2 hours after taking the combination tablet of sumatriptan 85 mg\u002Fnaproxen 500 mg.",{"measure":25,"description":26,"timeFrame":27},"Presence or absence of associated symptoms (nausea, vomiting, photophobia, or phonophobia)","Presence or absence of associated symptoms (nausea, vomiting, photophobia, or phonophobia) at predefined time intervals of 1, 2, 3, 4, 6, 8, 24, and 48 hours.","1-48 hours after taking combination of sumatriptan 85 mg and naproxen 500 mg",{"measure":29,"description":30,"timeFrame":31},"24 hour-sustained pain freedom","Percentage of patients experiencing complete pain relief within 2 hours after taking the combination of sumatriptan 85 mg and naproxen 500 mg, with sustained benefit in the following 24 hours (24h-sustained pain freedom).","24 hours after taking combination of sumatriptan 85 mg and naproxen 500 mg",{"measure":33,"description":34,"timeFrame":31},"24 hour sustained pain relief","Percentage of patients experiencing a 50% reduction in pain intensity within 2 hours after taking the combination of sumatriptan 85 mg and naproxen 500 mg, with sustained benefit in the following 24 hours (24h-sustained pain relief).",{"measure":36,"description":37,"timeFrame":12},"headache recurrence","Definition of the moment of possible migraine pain recurrence (headache recurrence), as well as its intensity within 24 and 48 hours following the administration of the medication (limited to patients who experienced pain freedom within 2 hours).",{"measure":39,"description":40,"timeFrame":31},"use of rescue medication","Use of rescue medications and evaluation of the time interval between the first and second dose.",{"measure":42,"description":43,"timeFrame":44},"Variation of Migraine Specific Quality of Life Questionnaire score at week 24","Changes in scores of the Migraine Specific Quality of Life Questionnaire administered at week 24 compared to baseline","week 24 after taking the first dose of combination of sumatriptan 85 mg and naproxen 500 mg",{"measure":42,"description":46,"timeFrame":44},"Changes in scores of the Migraine Specific Quality of Life Questionnaire administered at week 24 compared to week 12",{"measure":48,"description":43,"timeFrame":44},"Variation of Migraine Interictal Burden Scale score at week 24",{"measure":48,"description":50,"timeFrame":44},"Changes in score of the Migraine Interictal Burden Scale administered at week 24 compared to week 12",{"measure":52,"description":53,"timeFrame":44},"Variation of Headache Impact Test score at week 24","Changes in score of Headache Impact Test scale administered at week 24 compared to baseline",{"measure":55,"description":56,"timeFrame":44},"Variation of Headache Impact Test score score at week 24","Changes in score of Headache Impact Test scale administered at week 24 compared to week 12",{"measure":58,"description":59,"timeFrame":44},"Patient Global Impression of Change","Collection of subjective feedback from the patient regarding their experience with the medication, assessing patient satisfaction, ease of use of the medication, and perceived effectiveness with Patient Global Impression of Change scale",{"measure":61,"description":62,"timeFrame":63},"Adverse events occurrence","Definition of the type and number of adverse events occurring within 48 hours of taking the combination of sumatriptan 85 mg and naproxen 500 mg through a specific questionnaire (event details, duration, severity, and actions taken).","48 hours after taking the first dose of combination of sumatriptan 85 mg and naproxen 500 mg",null,{"allocation":64,"interventionModel":64,"interventionModelDescription":64,"primaryPurpose":64,"observationalModel":66,"timePerspective":67,"maskingInfo":64},"COHORT","PROSPECTIVE","Consecutive episodic or chronic migraine adults (with more than 4 migraine days per month) followed at the Headache Centers and have been prescribed at least one dose of sumatriptan 85 mg in combination with naproxen sodium 500 mg for the acute treatment of migraine will be enrolled.\n\nThe collection of demographic and clinical characteristics will be carried out through a direct interview using a detailed, semi-structured questionnaire during the screening\u002Fbaseline visit, when the prescription of the sumatriptan 85 mg and naproxen sodium 500 mg combination for migraine attacks will be issued. The follow-up visit will occur after 12 weeks (+\u002F-14 days) from the screening\u002Fbaseline visit, the end of study visit will take place after 24 weeks (+\u002F-14 days) from baseline.\n\nPatients will be provided with paper diaries for the following 12 weeks at screning\u002Fbaseline visit and at the follow up visit (at week 12). The paper diaries from the previous 12 weeks will be collected will be collected at week 12 and at week 24.\n\nThe following questionnaires will be administered:\n\n* Migraine Specific Quality of Life Questionnaire (MSQ)\n* Migraine Interictal Burden Scale (MIBS-4)\n* Headache Impact Test-6 (HIT-6) were administered at baseline\u002Fscreening visit, at follow-up visit (at week 12) and at the end of study visit.\n\nThroughout the study, any adverse events will be recorded and managed.","Consecutive adults with episodic migraine (EM) or chronic migraine (CM) with more than 4 days of migraine per month who attend Headache Centers and have been prescribed at least one dose of sumatriptan 85 mg in combination with naproxen 500 mg for the acute treatment of migraine will be enrolled.",[71],{"label":72,"type":64,"description":69,"interventionNames":73},"Migraineurs with >4 monthly migraine days",[74],"Drug: combination of sumatriptan 85 mg and naproxen 500 mg",[76],{"type":77,"name":78,"description":78,"armGroupLabels":79,"otherNames":64},"DRUG","combination of sumatriptan 85 mg and naproxen 500 mg",[72],[81,86],{"name":82,"role":83,"phone":84,"phoneExt":64,"email":85},"Piero Barbanti, MD, PhD","CONTACT","+393357071457","piero.barbanti@sanraffaele.it",{"name":87,"role":83,"phone":88,"phoneExt":64,"email":89},"Cinzia Aurilia, MD","3334147390","cinzia.aurilia@sanraffaele.it",{"type":91,"investigatorFullName":64,"investigatorTitle":64,"investigatorAffiliation":64,"oldNameTitle":64,"oldOrganization":64},"SPONSOR","100582872",false,"NCT06868953","Use of the Combination of Sumatriptan and Naproxen in the Acute Treatment of Migraine: Real World Evidence Study","SMART","Inclusion Criteria:\n\n1. Migraineurs (age ≥18 years, \\\u003C65 years) with at least 4 migraine days per month according to ICHD-3 criteria who have been prescribed the combination of sumatriptan 85 mg and naproxen 500 mg;\n2. Signed informed consent as required;\n3. Agreement to comply with all study procedures, including follow-up visits;\n4. Use of a contraceptive method by all participants throughout the study duration.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years or \\>65 years\n2. Pregnancy or breastfeeding\n3. Poor knowledge of the Italian language\n4. Comorbidities with other neurological, cardiovascular, hepatic, respiratory, hematological, or autoimmune diseases, or clinically significant laboratory abnormalities\n5. Inability to distinguish migraine attacks from tension-type headaches\n6. Migraine characterized by mild attacks or attacks that resolve spontaneously within 2 hours\n7. Hemiplegic or basilar migraine\n8. Headache with the use of acute medication on more than 10 days per month in each of the 3 months prior to screening\n9. Unwillingness to participate in the study -",true,"ALL","18 Years","65 Years",{"count":103,"type":104},300,"ESTIMATED","6 Months","OBSERVATIONAL","This is a multicenter, observational, prospective, real-life study that will be conducted at Headache Centers, aimed at confirming the efficacy and safety of the combination of sumatriptan 85 mg with naproxen 500 mg. The combination of sumatriptan 85 mg and naproxen sodium 500 mg is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients for whom sumatriptan monotherapy is insufficient. In two randomized studies, the sumatriptan\u002Fnaproxen sodium combination demonstrated significantly greater efficacy (65% of participants-n=1461-reported pain freedom at 2 hours) compared to sumatriptan alone (55%), naproxen sodium alone (44%), or placebo (28%) when used as a late therapy for a single migraine episode in adults. Similar results were observed in a second study (n=1495), with 57% of participants achieving pain freedom within 2 hours after taking the sumatriptan\u002Fnaproxen sodium combination, outperforming both sumatriptan monotherapy (50%) and naproxen sodium monotherapy (43%), as well as placebo (29%). This superiority was further assessed through sustained pain freedom over 24 hours, with an efficacy of 23-25% in participants treated with the sumatriptan\u002Fnaproxen combination compared to placebo (7-8%; p\\\u003C0.001 for both studies) and its individual components (sumatriptan monotherapy: 14%-16%; p=0.009 and p\\\u003C0.001, naproxen sodium monotherapy: 10%).\n\nIn four additional randomized studies, the combination was also found to be effective in menstrual migraine and dysmenorrhea, as well as in cases of poor response or intolerance to triptan therapy. In clinical trials, sumatriptan\u002Fnaproxen sodium was generally well tolerated, with an overall safety profile similar to that of sumatriptan. The most common adverse events were consistent with those expected for sumatriptan and naproxen sodium.",[109],"Migraine",[111],"migraine attack","NOT_YET_RECRUITING","2025-03-07",{"date":115,"type":116},"2025-03-11","ACTUAL",{"date":118,"type":104},"2025-04-10",{"date":120,"type":104},"2026-12-31",{"name":5,"class":6}]